Women’s Infertility - Pipeline Assessment and Market Forecasts to 2017

GlobalData, the industry analysis specialist, has released its new report, “Women's Infertility - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global women’s infertility therapeutics market. The report identifies the key trends shaping and driving the global women’s infertility therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global women’s infertility sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global women’s infertility market was valued at $1,417m in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% to reach $1,609m by 2017. The slow market growth is attributed to the patent expiry of the branded products such as Cetrotide and Ovidrel in 2015. Some key branded products, such as Cetrotide, GONAL-f, Crinone, Ovidrel, Luveris, Pergoveris and Puregon, are going to face a severe threat from generics as they approach patent expiry between 2010 and 2015

Companies Mentioned:

Merck & Co.
Dong-A Pharmaceuticals
Ferring Pharmaceuticals
PregLem SA
[Fade out the market survey infos]

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Women’s Infertility: Introduction 4
2.1 GlobalData Pipeline Report Guidance 4
3 Women’s Infertility: Market Characterization 5
3.1 Women’s Infertility Market Size 5
3.2 Women’s Infertility Therapeutics Market Forecast and CAGR 6
3.3 Drivers and Barriers for the Women’s Infertility Therapeutics Market 7
3.3.1 Drivers for the Women’s Infertility therapeutics market 7
3.3.2 Barriers for the Women’s Infertility therapeutics market 7
3.4 Opportunity and Unmet Need 7
3.5 Key Takeaway 8
4 Women’s Infertility: Competitive Assessment 9
4.1 Overview 9
4.2 Strategic Competitor Assessment 9
4.3 Major Marketed Products for Women’s Infertility 10
4.3.1 Clomid (clomiphene citrate) 10
4.3.2 Ovidrel (Choriogonadotropin Alfa) 10
4.3.3 GONAL-f (follitropin alfa) 11
4.3.4 Cetrotide (cetrorelix acetate) 12
4.4 Comparison of Major Marketed Products for Women’s Infertility 14
4.5 Key Takeaway 14
5 Women’s Infertility: Pipeline Assessment 15
5.1 Overview 15
5.2 Strategic Pipeline Assessment 15
5.2.1 Technology Trends Analytic Framework 15
5.3 Women’s Infertility Therapeutics – Promising Drugs under Clinical Development 17
5.4 Molecule Profile for Promising Drugs under Clinical Development 17
5.4.1 ELONVA (corifollitropin alfa injection) 17
5.5 Women’s Infertility Therapeutics – Clinical Pipeline by Mechanism of Action 18
5.6 Women’s Infertility Therapeutics – Pipeline by Clinical Phases of Development 19
5.6.1 Women’s Infertility Therapeutics – Phase III Clinical Pipeline 19
5.6.2 Women’s Infertility Therapeutics – Phase II Clinical Pipeline 20
5.6.3 Women’s Infertility Therapeutics – Phase I Clinical Pipeline 20
5.6.4 Women’s Infertility Therapeutics – Preclinical and Discovery Clinical Pipeline 20
5.7 Key Takeaway 20
6 Women’s Infertility: Implications for Future Market Competition 21
7 Women’s Infertility: Future Players in the Women’s Infertility Market 22
7.1 Introduction 22
7.2 Merck & Co. 22
7.2.1 Company Overview 22
7.2.2 Financial Performance 22
7.2.3 Business Description 23
7.3 Dong-A Pharmaceuticals 24
7.3.1 Company Overview 24
7.4 Ferring Pharmaceuticals 25
7.4.1 Company Overview 25
7.5 PregLem SA 26
7.5.1 Company Overview 26
8 Women’s Infertility: Appendix 27
8.1 Market Definitions 27
8.2 Scope of Pipeline Research 27
8.3 Abbreviations 27
8.4 Research Methodology 28
8.4.1 Coverage 28
8.4.2 Secondary Research 29
8.4.3 Forecasting 29
8.4.4 Primary Research 31
8.4.5 Expert Panel Validation 32
8.5 Contact Us 32
8.6 Disclaimer 32
8.7 Sources 32
[Fade out table of contents]

Table 1: Women’s Infertility Therapeutics Market, Global, Revenue ($m), 2001–2009 5
Table 2: Women’s Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2009–2017 6
Table 3: Comparison of Major Marketed Products for Women’s Infertility, 2010 14
Table 4: Women’s Infertility Therapeutics – Promising Drugs Under Clinical Development, 2010 17
Table 5: Women’s Infertility Therapeutics – Phase III Clinical Pipeline, 2010 19
Table 6: Women’s Infertility Therapeutics – Phase II Clinical Pipeline, 2010 20
Table 7: Women’s Infertility Therapeutics – Phase I Clinical Pipeline, 2010 20
Table 8: Women’s Infertility Therapeutics – Preclinical and Discovery Clinical Pipeline, 2010 20
Table 9: Merck & Co. – Women’s Healthcare Pipeline Products, 2010 24
Table 10: Merck & Co. – Women’s Infertility Pipeline Portfolio, 2010 24
Table 11: Dong-A Pharmaceutical Co., Ltd. – Women’s Health Pipeline Portfolio, 2010 25
Table 12: Dong-A Pharmaceutical Co., Ltd. – Women’s Infertility Pipeline Portfolio, 2010 25
Table 13: Ferring Pharmaceuticals – Women’s Health Pipeline Portfolio, 2010 26
Table 14: Ferring Pharmaceuticals – Women’s Infertility Pipeline Portfolio, 2010 26
Table 15: PregLem SA – Women’s Health Pipeline Portfolio, 2010 26
Table 16: PregLem SA – Women’s Infertility Pipeline Portfolio, 2010 26

Figure 1: Women’s Infertility Therapeutics Market, Global, Revenue ($m), 2001–2009 5
Figure 2: Women’s Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2009–2017 6
Figure 3: Opportunity and Unmet Need in the Women’s Infertility Market, 2010 8
Figure 4: Strategic Competitor Assessment of the Marketed Products for Women’s Infertility, 2010 9
Figure 5: Technology Trends Analytic Framework of Women’s Infertility Pipeline, 2010 16
Figure 6: Technology Trends Analytic Framework of Women’s Infertility Pipeline – Description, 2010 16
Figure 7: Women’s Infertility Therapeutics– Clinical Pipeline by Mechanism Of Action, 2010 18
Figure 8: Women’s Infertility Therapeutics Pipeline by Phase of Clinical Development, 2010 19
Figure 9: Women’s Infertility – Implications for Future Market Competition, 2010 21
Figure 10: Women’s Infertility Therapeutics Market – Clinical Pipeline by Company, 2010 22
Figure 11: GlobalData Methodology 28
Figure 12: GlobalData Market Forecasting Model 31
[Fade out list of tables / figures]